Gabather AB (SE:GABA)

:GABA

GABA

Gabather AB

RESEARCH TOOLSreports

Want to see SE:GABA full AI Analyst Report?

Gabather AB (GABA) Price & Analysis

0 Followers

GABA Stock Chart & Stats

kr0.04

>-kr0.01(-12.89%)

At close: Mar 06 4:00 PM EST

kr0.04

>-kr0.01(-12.89%)

Day’s Range― - ―

52-Week Rangekr0.02 - kr0.13

Previous CloseN/A

Volume42.79K

Average Volume (3M)488.51K

Market Cap

kr19.67M

Enterprise Valuekr6.31M

Total Cash (Recent Filing)kr3.14M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.05

Next Earnings

May 28, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding491,634,160

10 Day Avg. Volume541,248

30 Day Avg. Volume488,507

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-6.10

Price to Sales (P/S)0.00

P/FCF Ratio-0.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Specialized CNS Drug PlatformGabather's concentrated focus on small-molecule modulation of the GABAA receptor gives it deep domain expertise in a defined therapeutic niche. That focused platform supports intellectual property development and makes the company an attractive partner/licensee for larger pharma seeking CNS assets, creating a durable commercialization pathway if clinical progress continues.

Zero Reported DebtA zero-debt balance sheet materially lowers fixed financial obligations and bankruptcy risk for a pre-revenue biotech. This structural advantage preserves strategic flexibility for licensing or equity financings, enabling management to prioritize R&D and partner negotiations without near-term interest burdens.

Narrowing Net LossesThe multi-year trend of shrinking net losses suggests improved cost discipline, program prioritization or efficiency gains in R&D spending. For a clinical-stage biotech this reduces near-term financing pressure and improves the feasibility of reaching milestones or securing partner deals, a durable improvement if sustained.

Bears Say

Pre-revenueBeing pre-revenue means the company lacks operating cash inflows and is structurally dependent on external financing or partner deals to fund operations. That reliance increases dilution and execution risk, and until licensing or sales materialize the business model remains capital-intensive and funding-sensitive.

Negative EquityNegative shareholders' equity reflects accumulated losses that have eroded the capital base, reducing balance-sheet resilience. This constrains financing options (debt less feasible), can undermine counterparty confidence, and makes the company more likely to need dilutive equity raises to continue operations.

Persistent Cash BurnConsistent negative operating and free cash flow demonstrates ongoing cash burn and an unstable runway. The year-to-year swings raise funding unpredictability and heighten the likelihood of near-term financing needs; absent revenue or major partnering, this structural cash deficit is a sustained risk.

GABA FAQ

What was Gabather AB’s price range in the past 12 months?

Gabather AB lowest stock price was kr0.02 and its highest was kr0.13 in the past 12 months.

What is Gabather AB’s market cap?

Gabather AB’s market cap is kr19.67M.

When is Gabather AB’s upcoming earnings report date?

Gabather AB’s upcoming earnings report date is May 28, 2026 which is in 2 days.

How were Gabather AB’s earnings last quarter?

Gabather AB released its earnings results on Feb 26, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.

Is Gabather AB overvalued?

According to Wall Street analysts Gabather AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gabather AB pay dividends?

Gabather AB does not currently pay dividends.

What is Gabather AB’s EPS estimate?

Gabather AB’s EPS estimate is 0.

How many shares outstanding does Gabather AB have?

Gabather AB has 491,634,160 shares outstanding.

What happened to Gabather AB’s price movement after its last earnings report?

Gabather AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went up 18.519%.

Which hedge fund is a major shareholder of Gabather AB?

Currently, no hedge funds are holding shares in SE:GABA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gabather AB

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.